Giorgio Parmiani

Q: What Schools Are Affiliated With Giorgio Parmiani

Giorgio Parmiani is affiliated with the following schools: University of Milan, University of Melbourne, Vita-Salute San Raffaele University

Giorgio Parmiani's AcademicInfluence.com Rankings

Giorgio Parmiani

Biology

#8479

World Rank

#11563

Historical Rank

Immunology

#487

World Rank

#504

Historical Rank

biology Degrees

Download Badge

Biology

Giorgio Parmiani's Degrees

PhD Immunology University of Milan
Masters Biotechnology University of Milan
Bachelors Biology University of Milan

Similar Degrees You Can Earn

Best Online Bachelor's in Biology 2026

Why Is Giorgio Parmiani Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Giorgio Parmiani's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Phenotypic characterization of human colorectal cancer stem cells (2007) (2160)
Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE‐3 and presented by HLA‐A1 (1999) (854)
A listing of human tumor antigens recognized by T cells (2001) (807)
Induction of Lymphocyte Apoptosis by Tumor Cell Secretion of FasL-bearing Microvesicles (2002) (746)
Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. (2007) (678)
Therapeutic vaccines for cancer: an overview of clinical trials (2014) (610)
Interleukin-12: Biological Properties and Clinical Application (2007) (564)
A listing of human tumor antigens recognized by T cells: March 2004 update (2005) (483)
Tumour-released exosomes and their implications in cancer immunity (2008) (481)
Human colorectal cancer cells induce T-cell death through release of proapoptotic microvesicles: role in immune escape. (2005) (480)
Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytes. (2006) (478)
Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGES‐3 (1995) (447)
Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? (2002) (432)
Modulation of microenvironment acidity reverses anergy in human and murine tumor-infiltrating T lymphocytes. (2012) (432)
Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. (2004) (394)
Tumor-released microvesicles as vehicles of immunosuppression. (2007) (393)
Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. (2002) (387)
Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo (1991) (315)
Expression of MAGE genes in primary and metastatic cutaneous melanoma (1995) (297)
Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. (1996) (296)
Immunobiological Characterization of Cancer Stem Cells Isolated from Glioblastoma Patients (2010) (295)
Immunity to cancer: attack and escape in T lymphocyte–tumor cell interaction (2002) (293)
Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. (2006) (281)
A clinical development paradigm for cancer vaccines and related biologics. (2007) (274)
LAG-3 Expression Defines a Subset of CD4+CD25highFoxp3+ Regulatory T Cells That Are Expanded at Tumor Sites (2010) (264)
Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer. (2003) (259)
Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. (2012) (258)
Expression of cytokine/growth factors and their receptors in human melanoma and melanocytes (1994) (257)
Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. (2001) (250)
Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group. (2008) (242)
Cannibalism of live lymphocytes by human metastatic but not primary melanoma cells. (2006) (241)
Massive ex vivo generation of functional dendritic cells from mobilized CD34+ blood progenitors for anticancer therapy. (1995) (240)
Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes (1995) (218)
HOXB7 constitutively activates basic fibroblast growth factor in melanomas (1996) (218)
Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte cross-talk. (1992) (215)
BRAF alterations are associated with complex mutational profiles in malignant melanoma (2004) (212)
An Expanded Peripheral T Cell Population to a Cytotoxic T Lymphocyte (Ctl)-Defined, Melanocyte-Specific Antigen in Metastatic Melanoma Patients Impacts on Generation of Peptide-Specific Ctls but Does Not Overcome Tumor Escape from Immune Surveillance in Metastatic Lesions (1999) (212)
Human NK Cells Selective Targeting of Colon Cancer–Initiating Cells: A Role for Natural Cytotoxicity Receptors and MHC Class I Molecules (2013) (209)
beta2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma. (1998) (207)
Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1(27-35) (1996) (196)
Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma. (2003) (193)
Human heat shock protein 70 peptide complexes specifically activate antimelanoma T cells. (2001) (191)
Regression of an established tumor genetically modified to release granulocyte colony-stimulating factor requires granulocyte-T cell cooperation and T cell-produced interferon gamma (1993) (184)
Melanoma cells and normal melanocytes share antigens recognized by HLA- A2-restricted cytotoxic T cell clones from melanoma patients (1993) (181)
Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study (2015) (178)
Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma (2006) (165)
Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanoma. (1998) (164)
Unique Human Tumor Antigens: Immunobiology and Use in Clinical Trials1 (2007) (158)
Translation of a Retained Intron in Tyrosinase-related Protein (TRP) 2 mRNA Generates a New Cytotoxic T Lymphocyte (CTL)-defined and Shared Human Melanoma Antigen Not Expressed in Normal Cells of the Melanocytic Lineage (1998) (156)
Defining the critical hurdles in cancer immunotherapy (2011) (152)
Tumour-associated transplantation antigens of chemically induced sarcomata cross reacting with allogeneic histocompatibility antigens (1975) (140)
CD4 T cells inhibit in vivo the CD8‐mediated immune response against murine colon carcinoma cells transduced with interleukin‐12 genes (1995) (137)
Human CD4 lymphocytes specifically recognize a peptide representing the fusion region of the hybrid protein pml/RAR alpha present in acute promyelocytic leukemia cells. (1993) (134)
Human Tumor-Derived Heat Shock Protein 96 Mediates In Vitro Activation and In Vivo Expansion of Melanoma- and Colon Carcinoma-Specific T Cells1 (2003) (130)
A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-α in metastatic melanoma patients (2006) (128)
Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma. (2013) (128)
Targeting TNF-α to Neoangiogenic Vessels Enhances Lymphocyte Infiltration in Tumors and Increases the Therapeutic Potential of Immunotherapy (2012) (127)
Heat shock proteins: biological functions and clinical application as personalized vaccines for human cancer (2004) (127)
Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors. (2006) (122)
Consensus nomenclature for CD8+ T cell phenotypes in cancer (2015) (118)
Classes I and II HLA and melanoma-associated antigen expression and modulation on melanoma cells isolated from primary and metastatic lesions. (1986) (116)
Cytotoxic T lymphocyte clones from peripheral blood and from tumor site detect intratumor heterogeneity of melanoma cells. Analysis of specificity and mechanisms of interaction. (1989) (115)
Autologous dendritic cells derived from CD34+ progenitors and from monocytes are not functionally equivalent antigen-presenting cells in the induction of melan-A/Mart-1(27-35)-specific CTLs from peripheral blood lymphocytes of melanoma patients with low frequency of CTL precursors. (1997) (114)
Clonal analysis of cytotoxic T‐lymphocyte response to autologous human metastatic melanoma (1985) (113)
Selective Histocompatibility Leukocyte Antigen (Hla)-A2 Loss Caused by Aberrant Pre-mRNA Splicing in 624mel28 Melanoma Cells (1999) (111)
Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study. (2015) (111)
Occurrence of resistance to retinoic acid in the acute promyelocytic leukemia cell line NB4 is associated with altered expression of the pml/RAR alpha protein. (1993) (110)
A superagonist variant of peptide MART1/Melan A27-35 elicits anti-melanoma CD8+ T cells with enhanced functional characteristics: implication for more effective immunotherapy. (1999) (110)
Cytokines in cancer therapy. (2000) (108)
Cytotoxic T cells directed to tumor antigens not expressed on normal melanocytes dominate HLA-A2.1-restricted immune repertoire to melanoma. (1996) (102)
Role of Cross-Talk between IFN-α-Induced Monocyte-Derived Dendritic Cells and NK Cells in Priming CD8+ T Cell Responses against Human Tumor Antigens1 (2004) (101)
Heterogeneity in human melanoma cell adhesion to cytokine activated endothelial cells correlates with VLA-4 expression. (1991) (101)
T cell receptor (TCR) structure of autologous melanoma-reactive cytotoxic T lymphocyte (CTL) clones: tumor-infiltrating lymphocytes overexpress in vivo the TCR beta chain sequence used by an HLA-A2- restricted and melanocyte-lineage-specific CTL clone (1993) (101)
Expression of cytokine genes, including IL‐6, in human malignant melanoma cell lines (1992) (100)
Interleukin 12 potentiates the curative effect of a vaccine based on interleukin 2-transduced tumor cells. (1996) (98)
Analysis of TCR usage in human tumors: a new tool for assessing tumor-specific immune responses. (1995) (97)
The apoptosis inhibitor protein survivin induces tumor-specific CD8+ and CD4+ T cells in colorectal cancer patients. (2003) (97)
Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme (2014) (96)
Cancer-Initiating Cells from Colorectal Cancer Patients Escape from T Cell–Mediated Immunosurveillance In Vitro through Membrane-Bound IL-4 (2014) (96)
Clonal analysis of the cytolytic T-cell response to human tumors. (1987) (95)
Heterogeneity for integrin expression and cytokine‐mediated VLA modulation can influence the adhesion of human melanoma cells to extracellular matrix proteins (1991) (93)
Immunology of cancer stem cells in solid tumours. A review. (2014) (92)
Human melanoma-reactive CD4+ and CD8+ CTL clones resist Fas ligand-induced apoptosis and use Fas/Fas ligand-independent mechanisms for tumor killing. (1998) (91)
Effect Of Human Natural Killer and γδ T Cells on the Growth of Human Autologous Melanoma Xenografts in SCID Mice (2004) (89)
Phases of apoptosis of melanoma cells, but not of normal melanocytes, differently affect maturation of myeloid dendritic cells. (2001) (88)
Granulocyte colony-stimulating factor (G-CSF) gene transduction in murine adenocarcinoma drives neutrophil-mediated tumor inhibition in vivo. Neutrophils discriminate between G-CSF-producing and G-CSF-nonproducing tumor cells. (1992) (88)
Potent Phagocytic Activity Discriminates Metastatic and Primary Human Malignant Melanomas: A Key Role of Ezrin (2003) (87)
Limited antitumor T cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allogeneic melanoma cells. (1996) (87)
Boosting T Cell-Mediated Immunity to Tyrosinase by Vaccinia Virus-Transduced, CD34+-Derived Dendritic Cell Vaccination (2004) (87)
Peptides derived from self-proteins as partial agonists and antagonists of human CD8+ T-cell clones reactive to melanoma/melanocyte epitope MART1(27-35). (1998) (86)
Tumor immunity as autoimmunity: tumor antigens include normal self proteins which stimulate anergic peripheral T cells. (1993) (85)
Cytokine‐mediated modulation of HLA‐class II, ICAM‐1, LFA‐3 and tumor‐associated antigen profile of melanoma cells. comparison with anti‐proliferative activity by RIL1‐β, RTNF‐α, RIFN‐γ, RIl4 and their combinations (1990) (83)
Cellular immune response against autologous human malignant melanoma: are in vitro studies providing a framework for a more effective immunotherapy? (1990) (83)
Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 by HLA-A2 subtypes. Implications for peptide-based immunotherapy. (1996) (83)
Heterogeneous phenotype of human melanoma cells with in vitro and in vivo features of tumor-initiating cells. (2010) (83)
T‐cell recognition of melanoma‐associated antigens (2000) (82)
Immunology and immunotherapy of human cancer: present concepts and clinical developments. (2000) (82)
An explanation of the variable clinical response to interleukin 2 and LAK cells. (1990) (82)
Immunomodulating and Immunoresistance Properties of Cancer-Initiating Cells: Implications for the Clinical Success of Immunotherapy (2017) (82)
Human melanoma cells with high susceptibility to cell‐mediated lysis can be identified on the basis of icam‐1 phenotype, vla profile and invasive ability (1990) (80)
The susceptibility to natural killer cell‐mediated lysis of HLA class I‐positive melanomas reflects the expression of insufficient amounts of different HLA class I alleles (1998) (77)
In vitro anti‐tumor activity of eosinophils from cancer patients treated with subcutaneous administration of interleukin 2. Role of interleukin 5 (1993) (77)
Inhibition of proliferation by c-myb antisense oligodeoxynucleotides in colon adenocarcinoma cell lines that express c-myb. (1991) (76)
Escape strategies and reasons for failure in the interaction between tumour cells and the immune system: how can we tilt the balance towards immune-mediated cancer control? (2005) (75)
Immunotherapy of experimental metastases by vaccination with interleukin gene-transduced adenocarcinoma cells sharing tumor-associated antigens. Comparison between IL-12 and IL-2 gene-transduced tumor cell vaccines. (1996) (74)
Antigen-specific immunity in neuroblastoma patients: antibody and T-cell recognition of NY-ESO-1 tumor antigen. (2003) (73)
Immunological gene therapy with ex vivo gene-modified tumor cells: a critique and a reappraisal. (2000) (73)
Genes involved in melanoma: an overview of INK4a and other loci. (1999) (72)
Immunology and immunotherapy of colorectal cancer. (2003) (72)
Detection of mutated BRAFV600E variant in circulating DNA of stage III–IV melanoma patients (2007) (71)
Gene transfer into human dendritic antigen-presenting cells by vaccinia virus and adenovirus vectors. (1998) (71)
Targeting of interleukin 2 to human ovarian carcinoma by fusion with a single-chain Fv of antifolate receptor antibody. (1998) (69)
The inhibition of lymphocyte stimulation by autologous human metastatic melanoma cells correlates with the expression of HLA‐DR antigens on the tumor cells (1984) (68)
Heat Shock Proteins and Their Use as Anticancer Vaccines (2004) (68)
Clonal expansion of T lymphocytes in human melanoma metastases after treatment with a hapten-modified autologous tumor vaccine. (1997) (67)
NKG2D engagement of colorectal cancer‐specific T cells strengthens TCR‐mediated antigen stimulation and elicits TCR independent anti‐tumor activity (2003) (67)
Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides (2012) (65)
Melanoma immunology: past, present and future (2007) (64)
Multipeptide vaccination in cancer patients (2009) (62)
Role of the α5β1 Integrin Receptor in the Proliferative Response of Quiescent Human Melanoma Cells to Fibronectin (1992) (62)
CCN3/nephroblastoma overexpressed matricellular protein regulates integrin expression, adhesion, and dissemination in melanoma. (2008) (62)
Vaccination of melanoma patients with interleukin 4 gene-transduced allogeneic melanoma cells. (1999) (62)
Heterogeneity of clones from a human metastatic melanoma detected by autologous cytotoxic T lymphocyte clones (1986) (61)
Peptide-based vaccines for cancer therapy (2014) (60)
CDKN2A and CDK4 mutation analysis in Italian melanoma-prone families: functional characterization of a novel CDKN2A germ line mutation (2001) (59)
Soluble human LAG-3 molecule amplifies the in vitro generation of type 1 tumor-specific immunity. (2006) (59)
Expression of alien h‐2 specificities on a chemically induced balb/c fibrosarcoma (1977) (57)
Interleukin-6 expression in human neutrophil and eosinophil peripheral blood granulocytes (1993) (56)
Differential loss of T cell signaling molecules in metastatic melanoma patients' T lymphocyte subsets expressing distinct TCR variable regions. (1999) (55)
Novel HLA-Cw8-restricted T cell epitopes derived from tyrosinase-related protein-2 and gp100 melanoma antigens. (1999) (55)
Cytokine gene transduction in the immunotherapy of cancer. (1997) (54)
Adoptive transfer of an anti‐MART‐127–35‐specific CD8+ T cell clone leads to immunoselection of human melanoma antigen‐loss variants in SCID mice (2003) (54)
Naturally occurring peptides associated with HLA-A2 in ovarian cancer cell lines identified by mass spectrometry are targets of HLA-A2-restricted cytotoxic T cells. (2003) (54)
Tumor-infiltrating lymphocytes: their phenotype, functions and clinical use (1994) (54)
Differentiation of CD8+ T Cells from Tumor-Invaded and Tumor-Free Lymph Nodes of Melanoma Patients: Role of Common γ-Chain Cytokines1 (2003) (53)
Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patients (1994) (53)
Cutaneous melanoma in childhood and adolescence shows frequent loss of INK4A and gain of KIT. (2009) (52)
In vivo interleukin 2-induced activation of lymphokine-activated killer cells and tumor cytotoxic T-cells in cervical lymph nodes of patients with head and neck tumors. (1990) (52)
T-cell recognition of melanoma-associated antigens. (2000) (52)
Tumor-infiltrating T cells--friend or foe of neoplastic cells? (2005) (50)
Natural killer and NK-Like T-cell activation in colorectal carcinoma patients treated with autologous tumor-derived heat shock protein 96. (2005) (49)
Overexpression of the T-cell receptor beta-chain variable region TCRBV14 in HLA-A2-matched primary human melanomas. (1995) (49)
Identification of a Mutated Receptor-Like Protein Tyrosine Phosphatase κ as a Novel, Class II HLA-Restricted Melanoma Antigen1 (2003) (49)
Genetic modification of a carcinoma with the IL‐4 gene increases the influx of dendritic cells relative to other cytokines (1997) (49)
Differential patterns of HOX gene expression are associated with specific integrin and ICAM profiles in clonal populations isolated from a single human melanoma metastasis (1996) (48)
Immunotherapy of melanoma. (2003) (48)
Differences in frequency distribution of HLA-A2 subtypes between North American and Italian white melanoma patients: relevance for epitope specific vaccination protocols. (1996) (48)
T cell neoepitope discovery in colorectal cancer by high throughput profiling of somatic mutations in expressed genes (2015) (47)
Vaccination of Stage IV patients with allogeneic IL-4- or IL-2-gene-transduced melanoma cells generates functional antibodies against vaccinating and autologous melanoma cells (2002) (47)
Active immunization of metastatic melanoma patients with interleukin-2-transduced allogeneic melanoma cells: evaluation of efficacy and tolerability (1997) (47)
Effect of human natural killer and gammadelta T cells on the growth of human autologous melanoma xenografts in SCID mice. (2004) (46)
Susceptibility of chemoresistant murine and human tumor cells to lysis by interleukin 2-activated lymphocytes. (1988) (46)
TNK cells (NKG2D+ CD8+ or CD4+ T lymphocytes) in the control of human tumors (2009) (46)
PTPRK negatively regulates transcriptional activity of wild type and mutated oncogenic beta-catenin and affects membrane distribution of beta-catenin/E-cadherin complexes in cancer cells. (2008) (45)
Immunogenicity without immunoselection: a mutant but functional antioxidant enzyme retained in a human metastatic melanoma and targeted by CD8(+) T cells with a memory phenotype. (2005) (45)
Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients (2017) (44)
Interleukin-2 gene-transduced human melanoma cells efficiently stimulate MHC-unrestricted and MHC-restricted autologous lymphocytes. (1994) (44)
Future perspectives in melanoma research: meeting report from the “Melanoma Bridge”: Napoli, December 3rd–6th 2014 (2013) (42)
Factors, including transforming growth factor β, released in the glioblastoma residual cavity, impair activity of adherent lymphokine-activated killer cells (1993) (42)
Biochemical characterization of alien H-2 antigens expressed on a methylcholanthrene-induced tumor. (1979) (40)
Local Adoptive Immunotherapy of Advanced Head and Neck Tumors with Lak Cells and Interleukin-2 (1990) (40)
In vivo activation of lymphocytes in melanoma patients receiving escalating doses of recombinant interleukin 2 (1988) (39)
Melanoma Cancer Stem Cells: Markers and Functions (2016) (38)
International Meeting on Cancer Vaccines (2004) (38)
IMPAIRED H‐2 EXPRESSION IN B 16 MELANOMA VARIANTS (1983) (37)
An in vivo model to compare human leukocyte infiltration in carcinoma xenografts producing different chemokines (1995) (37)
Vaccination of patients with solid tumours. (2003) (37)
Characterization of a doxorubicin-resistant murine melanoma line: studies on cross-resistance and its circumvention. (1986) (37)
Suboptimal activation of CD8(+) T cells by melanoma-derived altered peptide ligands: role of Melan-A/MART-1 optimized analogues. (2003) (37)
Immunomodulation in a Treatment Program Including Pre- and Post-Operative Interleukin-2 and Chemotherapy for Childhood Osteosarcoma (2003) (36)
T‐cell‐receptor engagement and tumor ICAM‐1 up‐regulation are required to by‐pass low susceptibility of melanoma cells to autologous CTL‐mediated lysis (2009) (36)
Differential susceptibility to recombinant interferon-gamma-induced HLA-DQ antigen modulation among clones from a human metastatic melanoma. (1987) (36)
Role of T cells and tumour necrosis factor in antitumour activity and toxicity of flavone acetic acid. (1990) (36)
Universal and Stemness-Related Tumor Antigens: Potential Use in Cancer Immunotherapy (2007) (35)
Phenotypic and functional analysis of lymphocytes infiltrating paediatric tumours, with a characterization of the tumour phenotype (2005) (35)
Expression of Interleukin 1α, Interleukin 6, and Tumor Necrosis Factor α Genes in Human Melanoma Clones Is Associated with That of Mutated N-RAS Oncogene (1994) (35)
Interleukin-6 expression in human neutrophil and eosinophil peripheral blood granulocytes. (1993) (35)
NKG2D-Mediated Antitumor Activity by Tumor-Infiltrating Lymphocytes and Antigen-Specific T-Cell Clones Isolated from Melanoma Patients (2007) (35)
Recognition of melanoma-derived antigens by CTL: possible mechanisms involved in down-regulating anti-tumor T-cell reactivity. (1998) (34)
Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell response (2013) (33)
Multiple melanoma-associated epitopes recognized by HLA-A3-restricted CTLs and shared by melanomas but not melanocytes. (1996) (33)
Lack of T-cell-mediated recognition of the fusion region of the pml/RAR-alpha hybrid protein by lymphocytes of acute promyelocytic leukemia patients. (1996) (33)
Non-carcinogenicity of hexamethylenetetramine in mice and rats. (1968) (33)
MULTIPLE FOREIGN NON‐H‐2 DETERMINANTS ON THE SURFACE OF A CHEMICALLY‐INDUCED MURINE SARCOMA * (1977) (32)
Active immunization of metastatic melanoma patients with interleukin-4 transduced, allogeneic melanoma cells. A phase I-II study. (1994) (31)
Human Plasmacytoid Dendritic Cells Interact with gp96 via CD91 and Regulate Inflammatory Responses1 (2008) (31)
Non-Redundant Role for IL-12 and IL-27 in Modulating Th2 Polarization of Carcinoembryonic Antigen Specific CD4 T Cells from Pancreatic Cancer Patients (2009) (31)
Vaccination therapy in prostate cancer (2007) (30)
Somatically mutated tumor antigens in the quest for a more efficacious patient-oriented immunotherapy of cancer (2014) (30)
Somatic gene therapy of human melanoma: preclinical studies and early clinical trials. (1995) (29)
Immunodepression During Urethane and N-Nitrosomethylurea Leukaemogenesis in Mice (1971) (29)
T-cell response to unique and shared antigens and vaccination of cancer patients. (2002) (29)
Heterogeneous susceptibility of human melanoma clones to monocyte cytotoxicity: Role of ICAM‐1 defined by antibody blocking and gene transfer (1992) (29)
Effects of antitumour immunity on pregnancy in the mouse. (1973) (29)
Reconstitution of human telomerase reverse transcriptase expression rescues colorectal carcinoma cells from in vitro senescence: evidence against immortality as a constitutive trait of tumor cells. (2005) (29)
Down-regulation of interleukin 6 receptor alpha chain in interleukin 6 transduced melanoma cells causes selective resistance to interleukin 6 but not to oncostatin M. (1995) (29)
Multiple sub‐sets of Cd4+ and Cd8+ cytotoxic T‐cell clones directed to autologous human melanoma identified by cytokine profiles (1994) (28)
Vaccination: role in metastatic melanoma (2006) (28)
Type I consensus interferon (CIFN) gene transfer into human melanoma cells up-regulates p53 and enhances cisplatin-induced apoptosis: implications for new therapeutic strategies with IFN-alpha (2000) (28)
Sensi M, Nicolini G, Petti C, Bersani I, Lozupone F, Molla A et al.. Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma. Oncogene 25: 3357-3364 (2006) (27)
Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study (2016) (27)
Generation and phenotypic characterization of new human ovarian cancer cell lines with the identification of antigens potentially recognizable by HLA‐restricted cytotoxic T cells (1997) (27)
Jmmunodepressive and Leukemogenic Effects of Urethan in C3Hf and SWR Mice∗ (1969) (26)
Effect of anti‐embryo immunization on methylcholanthrene‐induced sarcoma growth in BALB/c mice (1974) (26)
Immunogenic strength of sarcomas induced by methylcholanthrene in millipore filter diffusion chambers. (1973) (25)
Cross‐reactions between tumor cells and allogeneic normal tissues. inhibition of a syngeneic lymphoma outgrowth in h‐2 and non‐h‐2 alloimmune balb/c mice (1982) (25)
TCR beta-chain variable region-driven selection and massive expansion of HLA-class I-restricted antitumor CTL lines from HLA-A*0201+ melanoma patients. (1997) (25)
Active immunization of metastatic melanoma patients with interleukin-2-transduced allogeneic melanoma cells: evaluation of efficacy and tolerability (1997) (24)
Cytotoxic T lymphocyte response against non-immunoselected tumor antigens predicts the outcome of gene therapy with IL-12-transduced tumor cell vaccine (1999) (24)
Modified peptides in anti-cancer vaccines: are we eventually improving anti-tumour immunity? (2009) (24)
T cell infiltration and prognosis in HCC patients. (2006) (23)
T cell responses in colorectal cancer patients: Evidence for class II HLA‐restricted recognition of shared tumor‐associated antigens (2000) (23)
Clinical protocol. Immunization of patients with malignant melanoma with autologous CD34(+) cell-derived dendritic cells transduced ex vivo with a recombinant replication-deficient vaccinia vector encoding the human tyrosinase gene: a phase I trial. (2003) (23)
Selective purging by human interleukin‐2 activated lymphocytes of bone marrows contaminated with a lymphoma line or autologous leukaemic cells (1991) (23)
Low TCR avidity and lack of tumor cell recognition in CD8+ T cells primed with the CEA-analogue CAP1-6D peptide (2007) (22)
Immune‐depressive effect of urethan on the homograft response in mice (1970) (22)
Lysis by activated lymphocytes of melanoma and small cell lung cancer cells surviving in vitro treatment with mafosfamide. (1987) (22)
N-Nitroso Compounds in the Environment. (1975) (22)
Autologous Versus Allogeneic Cell-Based Vaccines? (2011) (22)
Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. V. H‐2 associativity of variant‐specific antigens (1982) (22)
Type I interferon gene transfer sensitizes melanoma cells to apoptosis via a target activity on mitochondrial function. (2002) (22)
Conserved TCR usage by HLA-Cw* 1601-restricted T cell clones recognizing melanoma antigens. (1996) (22)
Immunogenicity of the ALLAVGATK (gp10017 – 25) peptide in HLA‐A3.1 melanoma patients (1998) (21)
A pilot Phase I study combining peptide-based vaccination and NGR-hTNF vessel targeting therapy in metastatic melanoma (2014) (21)
Growth of human melanoma xenografts is suppressed by systemic angiostatin gene therapy (2001) (21)
Expression of interleukin 1 alpha, interleukin 6, and tumor necrosis factor alpha genes in human melanoma clones is associated with that of mutated N-RAS oncogene. (1994) (21)
Systemic administration of autologous, alloactivated helper-enriched lymphocytes to patients with metastatic melanoma of the lung (2004) (21)
Melanoma antigens and their recognition by T cells. (2001) (21)
Successful adoptive immunotherapy with lymphokine-activated killer cells in the treatment of medulloblastoma disseminated via cerebrospinal fluid: case report. (1994) (20)
In vitro "spontaneous" neoplastic transformation of mouse fibroblasts in diffusion chambers. (1971) (20)
In vivo characterization of a doxorubicin resistant B16 melanoma cell line. (1986) (20)
Allostimulation of patients' lymphocytes generates both T and NK-like cells cytotoxic for autologous melanoma. (1985) (20)
High frequency of T cell clonal expansions in primary human melanoma. Involvement of a dominant clonotype in autologous tumor recognition (1999) (20)
Alloreactivity and tumor antigens: generation of syngeneic antilymphoma killer lymphocytes by alloimmunization of mice with normal cells. (1983) (20)
Clinical and immunologic responses in melanoma patients vaccinated with MAGE‐A3‐genetically modified lymphocytes (2013) (20)
Immune response to autologous human melanoma: implication of class I and II MHC products. (1986) (19)
Autologous tumor-derived HSPPC-96 vs. physician's choice (PC) in a randomized phase III trial in stage IV melanoma. (2006) (19)
Cytokine-based gene therapy of human tumors. An overview. (1996) (19)
Cell retargeting by bispecific monoclonal antibodies. Evidence of bypass of intratumor susceptibility to cell lysis in human melanoma. (1992) (19)
Human melanocytes and melanomas express novel mRNA isoforms of the tyrosinase-related protein-2/DOPAchrome tautomerase gene: molecular and functional characterization. (2000) (19)
Simultaneous transduction of B7-1 and IL-2 genes into human melanoma cells to be used as vaccine: enhancement of stimulatory activity for autologous and allogeneic lymphocytes (2001) (19)
Mitogenic activity of fibronectin and laminin on human melanoma is mediated by β1 integrins: 251 (1993) (19)
Mapping of HLA class I binding motifs in forty-four fusion proteins involved in human cancers. (1997) (19)
Proliferative and/or cytotoxic activity of lymphocyte clones to autologous human melanoma (1988) (19)
Activation of ras oncogenes and expression of tumor‐specific transplantation antigens in methylcholanthrene‐induced murine fibrosarcomas (1991) (18)
Transplacental Toxicity and Carcinogenesis Studies in Rats with Hexamethylenetetramine (1970) (18)
Human allogeneic melanoma‐reactive T‐helper lymphocyte clones: Functional analysis of lymphocyte‐melanoma interactions (1991) (18)
Lysis of autologous human melanoma cells by in vitro allosensitized peripheral blood lymphocytes (2004) (18)
Cytokine gene transduction in tumor cells: interleukin (IL)-2 or IL-4 gene transfer in human melanoma cells. (1994) (18)
Regulated expression of vascular cell adhesion molecule-1 in human malignant melanoma. (1992) (18)
Gene transfer in tumor therapy. (1994) (18)
Heat shock proteins gp96 as immunogens in cancer patients (2006) (17)
Limitations of the cancer stem cell theory (2008) (17)
Melanoma immunotherapy: new dreams or solid hopes? (1996) (17)
Integrating Immune Checkpoint Blockade with Anti-Neo/Mutated Antigens Reactivity to Increase the Clinical Outcome of Immunotherapy (2015) (16)
Ex vivo enrichment of circulating anti-tumor T cells from both cutaneous and ocular melanoma patients: clinical implications for adoptive cell transfer therapy (2011) (16)
Growth Characteristics of Human Colorectal and Non-Small Cell Lung Tumors Xenografted into Nude Mice: Possible Correlation with Prognosis (1986) (16)
Alien histocompatibility antigens on tumor cells (1979) (16)
Adoptive immunotherapy of advanced melanoma patients with interleukin-2 (IL-2) and tumor-infiltrating lymphocytes selected in vitro with low doses of IL-2 (1993) (16)
Tumor-associated transplantation antigen distinct from H-2k-like antigens on a BALB/c (H-2d) fibrosarcoma. (1978) (15)
Tumour immunotherapy: the adjuvant treatment of the 21st century? (2000) (15)
Two autologous melanoma‐specific and MHC‐restricted human T cell clones with identical intra‐tumour reactivity do not share the same TCR Vα and Vβ gene families (1991) (15)
Human dendritic cells: natural adjuvants in antitumor immunotherapy. (1998) (14)
Correlation between efficacy and toxicity in pts with pretreated advanced melanoma treated within the Italian cohort of the ipilimumab expanded access programme (EAP). (2013) (14)
Immunohistochemical analysis of the T-cell receptor beta-chain variable regions expressed by T lymphocytes infiltrating primary human melanoma. (1998) (14)
Future perspectives in specific immunotherapy of melanoma. (1998) (14)
Comparative assessment of TCRBV diversity in T lymphocytes present in blood, metastatic lesions, and DTH sites of two melanoma patients vaccinated with an IL-7 gene-modified autologous tumor cell vaccine (2002) (14)
Human Lymphocyte Activation Gene-3 Molecules Expressed by Activated T Cells Deliver Costimulation Signal for Dendritic Cell Activation1 (2008) (14)
P-glycoprotein gene amplification and expression in multidrug-resistant murine P388 and B16 cell lines. (1989) (14)
CEA and NCA Expressed by Colon Carcinoma Cells Affect their Interaction with and Lysability by Activated Lymphocytes (1992) (14)
Induction and functional characterization of β 2‐microglobulin (β2‐μ)‐free HLA class I heavy chains expressed by β2‐μ‐deficient human FO‐1 melanoma cells (1998) (13)
Preparation of antigenically active membranes from solid murine lymphomas and fibrosarcomas. (1979) (13)
Doxorubicin cellular pharmacokinetics and DNA breakage in a multi-drug resistant B16 melanoma cell line. (1988) (13)
A human melanoma cell line transduced with an interleukin-4 gene by a retroviral vector releases biologically active IL-4 and maintains the original tumor antigenic phenotype. (1995) (13)
Down-regulation of SPARC/osteonectin/BM-40 expression in methylcholanthrene-induced fibrosarcomas and in Kirsten-MSV transformed fibroblasts. (1991) (13)
Intralesional selection of T cell clonotypes in the immune response to melanoma antigens occurring during vaccination. (1998) (13)
DEPRESSION OF CELLULAR IMMUNE RESPONSE DURING SYNGENEIC PREGNANCY AS MEASURED BY THE GRAFT‐VERSUS-HOST REACTION (1975) (13)
Tumorigenicity and dissemination of primary and metastatic human melanomas implanted into different sites in athymic nude mice. (1988) (12)
Tumor rejection activity of antigens isolated from the membranes of a methylcholanthrene-induced sarcoma, C-1, bearing alien H-2 antigens. (1980) (12)
N-RAS mutations and susceptibility to lymphokine-activated killer (LAK) cells in human melanoma (1994) (12)
Active immunization of metastatic melanoma patients with IL-2 or IL-4 gene transfected, allogeneic melanoma cells. (1998) (12)
Lymphotoxin gene expression by melanocytes and melanoma cell lines and persistence of unspliced mRNA (1993) (12)
A phase II study combining ipilimumab and fotemustine in patients with metastatic melanoma: The NIBIT-M1 trial. (2011) (12)
Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: Data from the Italian cohort of ipilimumab expanded access programme (EAP). (2013) (12)
Role of the alpha 5 beta 1 integrin receptor in the proliferative response of quiescent human melanoma cells to fibronectin. (1992) (12)
T-cell recognition of melanoma antigens and its therapeutic applications (1997) (11)
Inhibition of Human Melanoma Growth in Nude Mice by Autologous, Alloactivated Peripheral Blood Lymphocytes (1984) (11)
Erratum: In vitro anti-tumor activity of eosinophils from cancer patients treated with subcutaneous administration of interleukin 2. Role of interleukin 5 (Int. J. Cancer, 54, 8-15 (1993)) (1993) (11)
Cytotoxic T-lymphoc ' te clones from different patients display limited T-cell-receptor variable-region gene usage in HLA-A 2-restricted recognition of the melanoma antigen MelanA / MART-1 (2005) (11)
Pre-clinical and clinical aspects of peptide-based vaccine against human solid tumors. (2011) (11)
In vivo reexpression of H-2 antigens in B16 melanoma cells. (1985) (11)
Cytokine-mediated modulation of HLA-class II, ICAM-1, LFA-3 and tumor-associated antigen profile of melanoma cells. Comparison with anti-proliferative activity by rIL1-beta, rTNF-alpha, rIFN-gamma, rIL4 and their combinations. (1990) (11)
Induction of Both CD8+ and CD4+ T-Cell–Mediated Responses in Colorectal Cancer Patients by Colon Antigen-1 (2008) (11)
Immunological approach to gene therapy of human cancer: improvements through the understanding of mechanism(s) (1998) (11)
Immune landscape and in vivo immunogenicity of NY-ESO-1 tumor antigen in advanced neuroblastoma patients (2018) (11)
LOSS OF POLYMORPHIC RESTRICTION FRAGMENTS OF CLASS I AND CLASS II MHC GENES IN A MALIGNANT MELANOMA (1986) (10)
Italian cohort of ipilimumab expanded access programme (EAP): Efficacy, safety, and correlation with mutation status in metastatic melanoma patients. (2013) (10)
Differences between in vivo and in vitro activation of cancer patient lymphocytes by recombinant interleukin 2: possible role for lymphokine-activated killer cell infusion in the in vivo-induced activation. (1989) (10)
Treatment of recurrent in transit metastases from cutaneous melanoma by isolation perfusion in extracorporeal circulation with interleukin‐2 and lymphokine activated killer cells. A pilot study (1992) (10)
Expression of retrovirus-related, cytotoxic T lymphocyte- and transplantation-defined antigens in NIH/3T3 transfectants after a single passage in nude mice. (1989) (9)
Tumor-associated alien alloantigens of BALB/c tumors encoded by the MHC and by non-H-2 genes: a histogenetic study. (1980) (9)
Effect of different sera on growth and "spontaneous" neoplastic transformation of mouse fibroblasts in vitro. (1974) (9)
Increased susceptibility to lymphokine activated killer (LAK) lysis of relapsing vs. newly diagnosed acute leukemic cells without changes in drug resistance or in the expression of adhesion molecules. (1992) (9)
Multiple VLA antigens on a subset of melanoma clones. (1990) (9)
β1-Integrins on Melanoma Clones Regulate the Interaction with Autologous Cytolytic T-Cell Clones (1992) (9)
ALIEN ANTIGENS ON TUMOUR CELLS REVISITED (1984) (8)
Lysis by interleukin 2-stimulated tumor-infiltrating lymphocytes of autologous and allogeneic tumor target cells (2004) (8)
Identification of a novel gp100/pMel17 peptide presented by HLA-A*6801 and recognized on human melanoma by cytolytic T cell clones. (2002) (8)
Preliminary results of contrast‐enhanced sonography in the evaluation of the response of uveal melanoma to gamma‐knife radiosurgery (2015) (8)
A randomized, phase III study of fotemustine versus the combination of fotemustine and ipilimumab or the combination of ipilimumab and nivolumab in patients with metastatic melanoma with brain metastasis: the NIBIT-M2 trial. (2015) (8)
Regression of established liver tumor induced by monoepitopic peptide-based immunotherapy (2005) (8)
Therapeutic use of a long-term cytotoxic T cell line recognizing a common tumour-associated antigen: The pattern of in vitro reactivity predicts the in vivo effect on different tumours (2005) (8)
Osteonectin transcript and metastatic behavior in v‐Ki‐ras transformed fibroblasts (1989) (8)
Alien H-2 antigens (H-2k) appearing on a methylcholanthrene-induced tumor (H-2d): biochemical characterization. (1980) (8)
Autologous cellular immune response to primary and metastatic human melanomas and its regulation by DR antigens expressed on tumor cells (2004) (7)
Human CD 4 Lymphocytes Specifically Recognize a Peptide Representing the Fusion Region of the Hybrid Protein pml / RARa Present in Acute Promyelocytic Leukemia Cells (2003) (7)
Tumor necrosis factor/cachectin and related cytokines (1989) (7)
An autologous T cell clone overcomes intra-melanoma heterogeneity for susceptibility to cell-mediated lysis by using multiple lytic mechanisms: in vitro and in vivo analysis. (1991) (7)
International Meeting “Immunotherapy of Cancer: Challenges and Needs” (2007) (7)
Chromosomal changes associated with urethan leukemogenesis in mice (1969) (7)
Effect of Prolonged Subcutaneous Administration of Interleukin-2 on the Orcadian Rhythms of Cortisol and Beta-Endorphin in Advanced Small Cell Lung Cancer Patients (1991) (7)
T lymphocytes can mediate lysis of autologous melanoma cells by multiple mechanisms: Evidence with a single T cell clone (2005) (7)
Anti-H-2 alloantibodies elicited by syngeneic immunizations with a chemically induced fibrosarcoma (1978) (7)
Genetic control of in vivo immunity to tumor‐specific transplantation antigens of chemically induced murine fibrosarcomas (1979) (7)
Adoptive immunotherapy of a BALB/c lymphoma by syngeneic anti-DBA/2 immune lymphoid cells: Characterization of the effector population and evidence for the role of the host's non-T cells (2004) (6)
Phase II multicenter trial of ipilimumab combined with fotemustine in patients with metastatic melanoma: The Italian Network for Tumor Biotherapy (NIBIT)-M1 trial. (2012) (6)
The NIBIT-M1 trial: Activity of ipilimumab plus fotemustine in patients with melanoma and brain metastases. (2012) (6)
The early antitumor immune response is necessary for tumor growth (2012) (6)
Alien Histocompatibility Determinants on the Cell Surface of Sarcomas Induced by Methylcholanthrene. II. in Vitro Serological Studies 1 (1977) (6)
NMU-1, a new transplantable mouse lung tumor: biological and chemosensitivity properties in vivo. (1985) (6)
Immunotherap y for colon cancer (1999) (6)
Nonimmunogenic sarcomas induced by 3-methylcholanthrene treatment of murine fibroblasts in diffusion chambers. (1975) (6)
ORIGINAL H‐2d AND FOREIGN H ‐ 2k ‐ LIKE ANTIGENS ARE INDEPENDENT ENTITIES ON A CHEMICALLY INDUCED SARCOMA (1978) (6)
Isolation perfusion in extracorporeal circulation with interleukin-2 and lymphokine-activated killer cells in the treatment of in-transit metastases from limb cutaneous melanoma (1995) (6)
Adoptive immunotherapy of cancer with immune and activated lymphocytes: Experimental and clinical studies (1986) (6)
Skin-graft rejection during lymphomagenesis in urethan-treated mice. (1971) (6)
Influence of the donors' clinical status on in vitro and in vivo tumor-cytotoxic activation of interleukin-2-exposed lymphocytes and their circulation in different organs (2004) (6)
Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients and modulation by GM-CSF-based anti-tumor vaccine (2007) (6)
Tumor Immunology: Molecularly Defined Antigens and Clinical Applications (2003) (6)
Induction and functional characterization of beta2-microglobulin (beta2-mu)-free HLA class I heavy chains expressed by beta2-mu-deficient human FO-1 melanoma cells. (1998) (6)
Adoptive immunotherapy of a mouse colon carcinoma with recombinant interleukin-2 alone or combined with lymphokine-activated killer cells or tumor-immune lymphocytes (2005) (6)
Immunodominance in the T-cell response to multiple non-H-2 histocompatibility antigens. V. Chromosomal mapping of the immunodominant cytotoxic T-cell target-1 (CTT-1) (2004) (5)
Increased Oncogenic Effect of a Low Dose of Methylcholanthrene in Immunodepressed Mice (1971) (5)
Phase II study of HSPPC-96 in combination with GM-CSF and IFN-α in stage IV malignant melanoma. (2004) (5)
Mechanisms for Tumor Killing and Use Fas / Fas Ligand-Independent CTL Clones Resist Fas Ligand-Induced Apoptosis + and CD 8 + Human Melanoma-Reactive CD 4 (1998) (5)
HLA Binding Characteristics and Generation of Cytotoxic Lymphocytes against Peptides Derived from Oncogenic Proteins (1997) (5)
Lack of anti-TSTA antibodies in mice immunized with a methylcholanthrene-induced fibrosarcoma (1981) (5)
Tumor-cell-targeted cytokine gene therapy. (1991) (5)
Can oncogene (RAS) activation predict susceptibility of human melanoma to activated lymphocytes and, therefore, the clinical response of such neoplasms to adoptive immunotherapy? (1992) (5)
Awareness and understanding of cancer immunotherapy in Europe (2014) (5)
Efficacy and safety data from elderly patients with pretreated advanced melanoma in the Italian cohort of ipilimumab expanded access programme (EAP). (2013) (5)
Lack of identity between TSTA and alien antigens of methylcholanthrene-induced murine sarcomas. (1980) (5)
Resistance of Cancer Stem Cells to Cell-Mediated Immune Responses (2015) (5)
Tumor antigens recognized by T cells and antibodies (2003) (5)
Retroviral heterogeneity in mouse lymphomas. (1988) (5)
Cytokine gene transfer in tumor cells as an approach to antitumor therapy (1992) (5)
DBA/2‐like minor histocompatibility antigens on a BALB/c lymphoma. A balb/c anti‐DBA/2 serum which lyses the tumor and blocks balb/c anti‐tumor and anti‐DBA/2 effectors (1985) (4)
Expression of H-2 and viral antigens and resistance to the antitumor lysis of tunicamycin-treated MBL-2 lymphoma cells. (1983) (4)
Chemokine Receptor 7, A New Player in Regulating Apoptosis of CD8+ T Cells in Cancer Patients (2005) (4)
LACK OF H‐2Ld LOCUS PRODUCTS ON A BALB/c FIBROSARCOMA EXPRESSING H‐2k‐LIKE ALIEN ANTIGENS (1983) (4)
COINCIDENT EFFECT IN THE GRAFT‐VERSUS‐HOST REACTION OF BALB/c LYMPHOID CELLS DERIVED FROM MICE IMMUNE EITHER TO ALLOGENEIC NORMAL TISSUE OR TO SYNGENEIC CHEMICALLYINDUCED FIBROSARCOMATA (1977) (4)
Mouse tumors are heterogeneous in their susceptibility to syngeneic lymphokine-activated killer cells and delineate functional subsets in such effectors (2005) (4)
Eradication of a disseminated mouse lymphoma by 1,3‐BIS(2‐chloroethyl)‐1‐nitrosourea is immunologically mediated and accompanied by de novo generation of anti‐tumor cytotoxicity (1990) (4)
The Role of Cytokines in the Modulation of Cell Surface Antigens of Human Melanoma (1993) (4)
A new Procedure for Large Scale Production and Freezing of Lymphokine Activated Killer (LAK) Cells to be used in Adoptive Immunotherapy of Cancer (1988) (4)
Antigens of chemically induced tumors. (1976) (4)
Control of human melanoma growth in nude mice by autologous allo‐activated peripheral blood lymphocytes (1986) (3)
Treatment of a low immunogenic experimental tumour with alloactivated or tumour-immune lymphocytes. (1987) (3)
The undefined relationship between tumor antigens and histocompatibility antigens on cancer cells (1980) (3)
The Italian Network for Tumor Biotherapy (NIBIT). Sharing Visions, Goals and Efforts at European Level (2008) (3)
Adjuvant multipeptide vaccination in high-risk early melanoma patients (2008) (3)
Carcinoma-Specific T Cells Expansion of Melanoma- and Colon Mediates In Vitro Activation and In Vivo Human Tumor-Derived Heat Shock Protein 96 (2003) (3)
Two autologous melanoma-specific and MHC-restricted human T cell clones with identical intra-tumour reactivity do not share the same TCR V alpha and V beta gene families. (1991) (3)
PHENOTYPIC HETEROGENEITY OF HLA PRODUCTS ON HUMAN MELANOMA CELLS (1986) (3)
Increasing immunogenicity of cancer vaccines to improve their clinical outcome (2013) (3)
Surgical Treatment of Melanoma: A Survey of Italian Hospitals (2013) (3)
Follow-Up of Melanoma: A Survey of Italian Hospitals (2013) (3)
Vaccination with survivin and PSMA-derived peptides for controlling biochemical recurrence in prostate cancer: A pilot study. (2016) (3)
Gene therapy of melanoma (2003) (3)
Cancer vaccination. (1999) (3)
BIOCHEMICAL ANALYSIS OF A PUBLIC H‐2 SPECIFICITY REVEALED BY AN ANOMALOUS REACTION OF AN ALLOANTISERUM WITH A CHEMICALLY INDUCED C57BL/10 FIBROSARCOMA (1982) (3)
Syngeneic Antitumor and Antiembryo Immunization Affecting Pregnancy in Mice 1 (1976) (3)
Lack of suppressive activity of human primary melanoma cells on the activation of autologous lymphocytes (2004) (3)
The Italian Network for Tumor Biotherapy (NIBIT): Getting together to push the field forward (2008) (3)
Cell surface antigens of chemically induced fibrosarcomas: detection by a monoclonal antibody of a tumor-restricted Mr 12,000 protein gag antigen encoded by a dual-tropic murine leukemia virus. (1985) (2)
Adjuvant adoptive immunotherapy with IL2 and lymphocytes from tumor-bearing mice: in vitro tumor-stimulated lymphocytes are more effective than LAK cells. (1991) (2)
NKG 2 D-Mediated AntitumorActivity by Tumor-Infiltrating Lymphocytes and Antigen-Specific T-Cell Clones Isolated fromMelanoma Patients (2007) (2)
When transgenes shape immunity: cancer immune‐gene therapy (2012) (2)
Inhibition of the YC8 lymphoma growth by alloimmunization with normal cells. (1981) (2)
Gene therapy in melanoma. (2001) (2)
Susceptibility of human and murine drug-resistant tumor cells to the lytic activity of rIL2 - activated lymphocytes (LAK) (1988) (2)
Histocompatibility Antigens on the Cell Surface of Tumors (1983) (2)
Conference on cancer vaccines (2000) (2)
Role of the Immune System in the Growth of an Isotransplanted Urethan-Induced Lymphosarcoma (1969) (2)
T cell response to tumor antigens and its therapeutic use in cancer patients. (2001) (2)
A merging duo in melanoma formation. (2005) (2)
H‐2K RESTRICTION OF THE T CELL‐MEDIATED LYSIS OF A CHEMICALLY‐INDUCED BALB/c FIBROSARCOMA (1983) (2)
Immunotherapy for colon cancer. (1999) (2)
Analysis of the cellular immune response to and adoptive immunotherapy of a BALB/c lymphoma that cross-reacts with normal DBA/2 cells (2004) (2)
Generation of TSTA diversity (1983) (2)
Immunobiology and Use in Clinical Trials Unique Human Tumor Antigens: (2)
Strain polymorphism and tentative mapping of mouse ornithine decarboxylase. (1988) (2)
Re-visiting Prehn's hypothesis in the human melanoma system (2012) (2)
Microenvironment and Immunology Modulation of Microenvironment Acidity Reverses Anergy in Human and Murine Tumor-In fi ltrating T Lymphocytes (2012) (2)
Lack of cross-resistance of a doxorubicin-resistant B16 melanoma line with 4'-deoxy-4'-iodo-doxorubicin (2004) (2)
Awareness and understanding of cancer immunotherapy in Europe. (2013) (2)
Autologous cellular immune response in cancer today (1991) (2)
Beta 1-integrins on melanoma clones regulate the interaction with autologous cytolytic T-cell clones. (1992) (2)
Adoptive immunotherapeutic treatments with interleukin 2 and lymphocytes in a mouse colonic adenocarcinoma model. (1990) (2)
Melanoma: The Milan Melanoma Cell Lines (2002) (2)
Induction of autologous human melanoma killer lymphocytes by allostimulation (1985) (1)
Immunogenic Neoplastic Clones Derived in Vitro from an Originally Non-immunogenic BALB/c Fibrosarcoma 1 (1977) (1)
Melanoma Antigens Derived from Tyrosinase-Related Protein-2 Novel HLA-Cw 8-Restricted T Cell Epitopes (1999) (1)
Biochemical characterization of the anomalous reaction of anti-H-2b alloantiserum with a chemically induced sarcoma of H-2k origin. (1981) (1)
Vaccine Therapy of Cancer (2002) (1)
H-2 class I gene analysis in 3-methylcholanthrene-induced murine fibrosarcomas. (1990) (1)
Tumor-Derived Exosomes as Dendritic Cell Modulators (2009) (1)
Immune mechanisms in neoplasia (2004) (1)
Genetic control of responsiveness to the tumor-associated transplantation antigen of a chemically induced murine fibrosarcoma (1978) (1)
T cell-defined melanoma antigens: toward a tumour-specific immunotherapy of the disease. (1993) (1)
Adoptive Immunotherapy of Melanoma with Interleukin-2 and Lymphocytes (1993) (1)
Frequency of CTL precursors and effectors directed to a single peptide of melan-A/Mart-1: Evidence for heterogeneity among HLA-A*0201+melanoma patients (1997) (1)
Adoptive immunotherapy with adherent lymphokine-activated killer (A-LAK) cells in glioblastoma multiforme. (1990) (1)
Study of the immunogenic strength of sarcomas induced in diffusion chambers. (1972) (1)
Abnormal expression of histocompatibility antigens on cancer cells. (1982) (1)
Cancer vaccines. (2000) (1)
Foxp 3 highCD 25 + LAG-3 Expression Defines a Subset of CD 4 Parmiani (2010) (1)
Defective T helper activity in the spleen of BALB/c mice immune to a syngeneic fibrosarcoma (2004) (1)
Neutrophils discriminate between G-CSF producing and non-producing colon carcinoma cells: correlation with tumor inhibition (1991) (1)
What is new in melanoma research? Vaccines, Basic and Translational Research in 2003: report of a workshop at the Third Research Meeting on Melanoma, Milan, Italy, May 2003 (2004) (1)
Cancer patients' lymphocytes contain CD3+CD4+cells that proliferate in response to autologous tumor cells in the presence of exogenous low-dose interleukin-2 and autologous accessory cells (2005) (1)
Postsurgical adjuvant chemoimmunotherapy with recombinant interleukin-2 and 1,3-bis-(2-chloroethyl)-1-nitrosurea on spontaneous metastases of a non-immunogenic murine tumour (2005) (1)
Histocompatibility antigens and tumour antigens (1980) (1)
11 Recent developments of immunotherapy in melanoma patients.The experience of Milano National Cancer Institute (1997) (1)
Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme (2014) (1)
Improved survival for stage III/IV melanoma from an unknown primary site (MUP): An Italian multicentric study. (2010) (1)
Effect of anti-tumor immunity on pregnancy in the mouse. Abstr. (1973) (1)
Optimized Analogues Altered Peptide Ligands : Role of MelanA / MART-1 T Cells by Melanoma-derived + Suboptimal Activation of CD 8 Updated Version (2003) (0)
Eighth annual meeting of the Italian network for tumor biotherapy (NIBIT), Siena, October 7–9, 2010 (2011) (0)
Subject Index, Vol. 44, 1976 (1976) (0)
Human tumor vaccines go molecular (1995) (0)
MHC class I antigens and somatic mutants. (1987) (0)
Hox gene expression in parallel clonal populations derived from a single human melanoma metastasis: 239 (1993) (0)
9 A phase I study of immunization with dendritic cells transduced with a vaccinia vector encoding the human tyrosinase gene in patients with metastatic melanoma (2004) (0)
Treatment of stage IV melanoma patients with interleukin-2 (IL-2) and autologous tumor infiltrating lymphocytes (TIL): 291 (1993) (0)
Vaccination-induced myeloid suppressor cells in melanoma: phenotypic and functional characterization (2007) (0)
Interaction of Cytotoxic T Lymphocytes with Autologous Melanoma: Role of Adhesion Molecules and β1 Integrins (1993) (0)
Tata and alien h-2 are distinct antigens on the cell surface of a chemically induced fibrosarcoma. Abstr. (1978) (0)
Characterization of the immune profile of cancer stem cells isolated from human glioblastoma (2008) (0)
Late abstracts 186–187 (2005) (0)
Regulation and effect of TNFβ expression in melanoma cell lines: 283 (1993) (0)
Inflammatory Responses with gp96 via CD91 and Regulate Human Plasmacytoid Dendritic Cells Interact (2008) (0)
“Cancer Bio-Immunotherapy in Siena”: Thirteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 8–10, 2015 (2016) (0)
Libri Ricevuti: Principles of Cancer Biotherapy (1992) (0)
Serologically detected foreign alloantigens of a chemically induced murine sarcoma. Abstr. (1976) (0)
Induction of myeloid cells with suppressive activity by human tumor-released microvesicles (2006) (0)
Regulated Expression ofVascular Cell Adhesion Molecule-1 inHuman Malignant Melanoma (1992) (0)
Biology of Amphibian Tumors (1970) (0)
Immunotherapy of tumors. Introduction. (1994) (0)
Evaluation of Myeloid Suppressive Cells in Peripheral Blood of Melanoma Patients and Their Modulation by A Heat-shock Protein (HSP)-96 and GM-CSF-based Vaccine (2005) (0)
CCN3/NOV matricellular protein is expressed in melanoma progression (2006) (0)
TCR Variable Regions T Lymphocyte Subsets Expressing Distinct Molecules in Metastatic Melanoma Patients' Differential Loss of T Cell Signaling (1999) (0)
Differences between in Vivoand in Vitro Activation of Cancer Patient Lymphocytes by Recombinant Inter leukin 2 : Possible Role for Lymphokine-activated Killer Cell Infusion in the in F / vo-induccd Activation 1 (2006) (0)
Immune correlates of metastatic melanoma patients treated with ipilimumab in combination with fotemustine in the phase II NIBIT-M1 study (2013) (0)
Involvement of somatically acquired ecotropic viruses in the immunogenicity of nude-transplanted NIH/3T3 transformed cell lines. (1992) (0)
Ly-5.185 molecule is associated with thymic maturation of lymphocytes but not with their cytotoxic activity. (1987) (0)
Chain Cytokines γ Common Nodes of Melanoma Patients : Role of Tumor-Invaded and Tumor-Free Lymph T Cells from + Differentiation of CD 8 Parmiani and (2003) (0)
Treatment of in transit metastases from cutaneous melanoma by isolation perfusion (IP) with interleukin-2 (IL-2) and lymphokine activated killer cells (LAK): 356 (1993) (0)
Binding, presentation and immunogenicity of peptides derived from melanoma antigens MART1 and GPZOO by HLA-A2 subtypes (1996) (0)
Surgery, Radiotherapy, Chemotherapy, Hormonal Therapy (1989) (0)
Validation of Stereotyped Immunoglobulin Heavy Chain CDR3 Sequences As Candidate Antigens for Immunotherapy of CLL (2012) (0)
Alloimmunization-induced syngeneic antitumor immunity in balb/c mice. Abstr. (1982) (0)
997 Active immunization of melanoma patients with IL-2-transfected allogeneic melanoma cells. A phase I-II study (1995) (0)
Active immunization of melanoma patients with IL-2-OR IL-4-transduced allogeneic melanoma cells (1997) (0)
Polygenic control of the in vivo immunity to balb/c sarcomas and lymphomas. Abstr. (1980) (0)
Therapeutic effect of chemoimmunotherapy on lymphoma bearing mice (1987) (0)
Abstracts reprinted from journal of clinical oncology (2007) (0)
Sixth annual meeting of the Italian network for tumor biotherapy (NIBIT), Siena, 16–18 October 2008 (2009) (0)
LAG-3 (CD223) molecule is preferentially expressed in human CD4+CD25+ T cells displaying suppressor activity (2007) (0)
Coincedent effect in the graft-versus-host reaction of BALB/c lymphoid cells derived from mice immune either to allogeneic normal tissue or to syngeneic chemically induced fibrosarcomata. (1977) (0)
Advances in Brief Heterogeneity in Human Melanoma Cell Adhesion to Cytokine Activated Endothelial Cells Correlates with VLA-4 Expression 1 (2006) (0)
Biological and biochemical characterization of alien h-2 antigens of a chemically induced sarcoma. Abstr. (1979) (0)
O11 Final analysis of a phase I/II study with CV9103: An intradermally administered prostate cancer vaccine based on self-adjuvanted mRNA (RNActive®) (2012) (0)
Vaccination with T Cell-Defined Antigens: Biological Basis and Clinical Applications (2001) (0)
Ly-5 molecular forms in congenitally immunodeficient mice. (1984) (0)
Activity of np-40 solubilized and enriched tata from an mca-induced balb/c sarcoma containing alien h-2k antigens. Abstr. (1979) (0)
Reactivity of human lymphocyte clones to autologous metastatic melanoma cells. (1988) (0)
Multiple composition of foreign alloantigens on a murine fibrosarcoma. Abstr. (1976) (0)
Tumor vaccines (WS-070) Chairpersons: Yutaka Kawakami, Olivera Finn (2010) (0)
Ninth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), Siena, Italy, October 19–22, 2011: New perspectives in the immunotherapy of cancer (2012) (0)
Isolation of lymphocyte clones reacting against autologous human melanoma (1987) (0)
5-Fluorouracil (5-FU) + Cis-diamminedichloroplatinum (DDP) Treatment of Human Colorectal Tumor Xenografts (1988) (0)
Recognition of lineage-specific antigens on melanoma and melanocytes by HLA-A2-restricted cytolytic T cell clones: 75 (1993) (0)
Special Topics in Carcinogenesis (1975) (0)
A TaqI RFLP at the gas-2 locus. (1989) (0)
Potential therapeutic use of autologous human lymphocytes in metastatic melanoma: in vivo interleukin 2-activated peripheral blood lymphocytes and in vitro activated peripheral blood and tumor-infiltrating lymphocytes. (1988) (0)
IFN-Alpha as an adjuvant in cancer immunotherapy (2006) (0)
Role of the a$ÃŸiIntegrin Receptor in the Proliferative Response of Quiescent Human Melanoma Cells to Fibronectin1 (2006) (0)
Natural Cytotoxicity Receptors and MHC Initiating Cells : A Role for − Colon Cancer Human NK Cells Selective Targeting of Dieli (2013) (0)
Cell Activation Deliver Costimulation Signal for Dendritic Molecules Expressed by Activated T Cells Human Lymphocyte Activation Gene-3 Parmiani and (2008) (0)
Immunotherapy of cancer with interleukin-2 and lymphocytes (LAK or TIL). (1992) (0)
Immune landscape and in vivo immunogenicity of NY-ESO-1 tumor antigen in advanced neuroblastoma patients (2018) (0)
In vitro lymphocyte response to autologous melanoma: clues in designing new adoptive immunotherapy protocols. (1989) (0)
Role of the carbohydrate prosthetic groups in the biosynthesis of membrane antigens and in the H-2-restricted lysis of MBL-2 lymphoma cells. (1983) (0)
Non-H-2 foreign alloantigens on chemically induced sarcoma cells as detected by graft-versus-host reaction [proceedings]. (1976) (0)
present in acute promyelocytic leukemia cells representing the fusion region of the hybrid protein pml/RAR alpha Human CD4 lymphocytes specifically recognize a peptide (2011) (0)
Retrovirus mediated expression of interleukins for the gene therapy of cancer (1997) (0)
Active immunization of metastatic melanoma patients with IL-2 gene-transferred, allogeneic melanoma cells (1996) (0)
Contents, Vol. 44, 1976 (1976) (0)
7019 Vaccination with Survivin and PSMA-derived peptides: results of a pilot study in prostate cancer patients failing radiotherapy or surgery (2009) (0)
Erratum: Immune mechanisms in neoplasia (2005) (0)
Cytokine gene-transduced tumor cells in cancer therapy: Tumor inhibition by non-specific and specific immune mechanisms (1993) (0)
Vaccination with gene-modified tumor cells (1999) (0)
“Cancer Bio-Immunotherapy in Siena”: Eleventh Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 17–19, 2013 (2014) (0)
V a c c ination o f M etastatic M elanoma P atients W ith Autologous T umor-Derived H eat S hock P rotein g p96- Peptide C omplexes: C linical a nd I mmunologic F indings (2002) (0)
Studies of cell-mediated immunity to alien h-2k-like antigens of a balb/c(h-2d) fibrosarcoma. Abstr. (1979) (0)
A microsatellite in the coding sequence of HLA-A/B is a mutation hotspot in colon cancer with microsatellite instability. (2021) (0)
T-cell receptor usage in T lymphocyte clones specifically recognizing human melanoma: 91 (1993) (0)
Dendritic cells from peripheral blood cd34+ progenitors in cancer patients treated with high dose sequential theraphy (1996) (0)
Interleukin-2 biology and immunology (1993) (0)
Vaccination in Human Solid Tumors: Recent Progress in the Clinical Arena (2015) (0)
Immunization of stage IV melanoma patients with MART-1 and GP100 peptides together with IFN-alpha as adjuvant results in an increased number of monocytes/dendritic cell precursors (2004) (0)
Tumor antigens as modified normal cell surface antigens. (1983) (0)
Immunological approach to gene therapy of melanoma: 084 (1997) (0)
Cancer Epidemiology, Environmental Factors. (1975) (0)
Tenth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), SIENA, Italy, November 5–7, 2012 (2013) (0)
23 Development of heat shock cancer vaccine strategies (2004) (0)
Seventh annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), Siena, 1–3 October 2009 (2010) (0)
HLA Class II Antigens on Melanoma Cells (1990) (0)
“Cancer Bio-Immunotherapy in Siena”: Twelfth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 9–11, 2014 (2015) (0)
T Cell Receptor (TCR) Structure of Autologous Melanoma-reactive Cytotoxic T Lymphocyte (CTL) Clones: Tumor-lnfiltrating Lymphocytes Overexpress In Vivo the TCR f3 Chain Sequence Used by an HLA-A2-restricted and Melanocyte-lineage-specific (2003) (0)
myb That Express c-Oligodeoxynucleotides in Colon Adenocarcinoma Cell Lines Antisense myb Inhibition of Proliferation by c-Updated Version (2006) (0)
Eradication of a disseminated BALB/c mice lymphoma by adoptive transfer of syngeneic anti-DBA/2 T lymphocytes does not require the partecipation of radiation-sensitive host cells (1985) (0)
Screening Tests in Chemical Carcinogenesis (1976) (0)
INV 28 Vaccination-induced myeloid suppressor cells in melanoma: phenotypic and functional characterization (2007) (0)
Vaccination with T cell-defined antigens: biological basis and clinical applications. (2001) (0)
Vaccination with Survivin and PSMA-derived Peptides: A Pilot Study in Prostate Cancer Patients Failing Radiotherapy or Surgery (2009) (0)
Latency, antigenicity and ras gene activation of methyl-cholanthrene- induced murine fibrosarcomas (1987) (0)
Recombinant interferon-gamma differently affects DQA and DRA gene expression in two human melanoma clones: transcriptional and posttranscriptional regulation. (1991) (0)
Future perspectives in melanoma research: meeting report from the “Melanoma Bridge”: Napoli, December 3rd–6th 2014 (2015) (0)
Update on vaccines for melanoma patients (2008) (0)
Immunological therapy of human tumors by gene-modified cellular vaccines. (2000) (0)
Immunomodulation in Cancer Patients Treated with Interleukin-2. Induction of Non-Specific and Specific Immune Responses (1993) (0)
Immunological and clinical effects of a multiple peptide vaccine and low-dose cyclophosphamide in prostate carcinoma patients (2016) (0)
1275 Preliminary clinical results of active immunization with interleukin-4 gene transfected allogeneic melanoma cells in metastatic melanoma patients (1995) (0)
Altered peptide ligands of tumor T-cell epitopes: implications for more effective vaccine therapy in human neoplasia (2003) (0)
In vitro detection of cell-mediated immunity to individual tumor-specific antigens of methylcholanthrene induced balb/c fibrosarcomas. Abstr. (1983) (0)
T cell recognition of melanoma-derived antigens: Implication for peptide based immunotherapy (1997) (0)
23 T cell recognition of melanoma antigens and tumour progression (1999) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Giorgio Parmiani?

Giorgio Parmiani is affiliated with the following schools:

Giorgio Parmiani's Academic­Influence.com Rankings